



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

10 November 2022

**Notice under section 708A(5)(e) of the Corporations Act 2001
Telix Pharmaceuticals Limited (ASX Code: TLX) (“Company”)**

Reference is made to the Appendix 2A released on 10 November 2022 and the issue of fully paid ordinary shares in Telix Pharmaceuticals Limited (“Shares”). For the purposes of section 708A(5)(e) of the Corporations Act, the Company gives notice that:

- (a) On 9 November 2022 the Company issued 495,000 Shares upon the exercise of 495,000 unlisted Share Options;
- (b) The Company issued the shares without disclosure under part 6D.2 of the Corporations Act;
- (c) As at the date of this notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act; and
- (d) As at the date of this notice there is no information which is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

Authorised for release by

A handwritten signature in blue ink, appearing to read "Melanie Farris", is positioned above the printed name and title.

Melanie Farris
Group Company Secretary